{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:30:18Z","timestamp":1792553418251,"version":"4.5.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n The choice of first line hormonal therapy in metastatic hormone-sensitive prostate cancer (mHSPC) is often based on comorbidities or physician preference due to the lack of data comparing abiraterone and enzalutamide in clinical trials and in clinical practice settings, especially in African American patients.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare clinical outcomes in patients with mHSPC treated with abiraterone acetate or enzalutamide.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study included all patients with mHSPC diagnoses in the US Veterans Affairs Health Care system who initiated abiraterone or enzalutamide between July 2017 and April 2023. Data were analyzed from April 2024 to March 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Receipt of abiraterone acetate or enzalutamide.<\/jats:p>\n <\/jats:sec>\n \n Main outcomes and measures<\/jats:title>\n \n Drug outcomes were established by estimating rates of tumor growth (\n g<\/jats:italic>\n -rates) using prostate-specific antigen (PSA) values while receiving therapy and measuring overall survival (OS). Two different matching analyses were performed: inverse probability weighting (IPW) and 1:1 exact matching.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 1258 patients (median [IQR] age, 73 [69-79] years; 314 [25.0%] African American, 857 [68.1%] White, and 87 [6.9%] with other or unknown race) who received abiraterone and 311 patients (median [IQR] age, 74 [69-79] years; 84 [27.0%] African American, 207 [66.6%] White, and 20 [6.4%] with other or unknown race) who received enzalutamide were included. In the unweighted analysis, the abiraterone cohort had median (IQR)\n g<\/jats:italic>\n -rate of 0.000137\/d (0.000094-0.001519) and the enzalutamide cohort, 0.000137\/d (0.000098-0.001815); median (IQR) OS was 36.2 (32.8-38.8) months for abiraterone and 36.2 (34.1-40.5) months for enzalutamide, with a median (IQR) follow-up of 28.7 (15.6-45.6) and 30.8 (16.1-39.1) months, respectively. In IPW analysis, using abiraterone as reference, the weighted median OS was comparable between abiraterone and enzalutamide in the full cohort (36.2; 95% CI, 32.8-38.8 vs 35.5; 95 % CI, 32.9-40.4 months; hazard ratio [HR], 1.09; 95% CI, 0.92-1.30;\n P<\/jats:italic>\n \u2009=\u2009.32), African American veterans (39.7; 95% CI, 34.3-46.6 vs 40.3; 95% CI, 34.3-not reached months; HR, 0.98; 95% CI, 0.72-1.34;\n P<\/jats:italic>\n \u2009=\u2009.90) and those with cardiovascular disease (31.5; 95% CI, 28.1-35.5 vs 35.0; 95% CI, 30.7-38.9; HR, 1.12; 95% CI, 0.91-1.37;\n P<\/jats:italic>\n \u2009=\u2009.30). In 1:1 matched analysis, both the abiraterone and enzalutamide groups had 279 patients with 63 (23%) who were African American; these patients had a median (IQR) follow-up of 27.3 (15.3-40.8) and 31.1 (16.8-39.9) months, respectively. The 1:1 matched cohort consisted of 158 patients (57%) in each group with an initial Gleason score of 8 or higher, and 224 patients (80%) in each group with a PSA value of 50 ng\/mL or higher at treatment initiation. For the 1:1 matched cohort and its subgroups of African American patients, patients with Gleason scores of 8 or higher, and patients with a starting PSA level of 50 ng\/mL or higher, no statistically significant difference in median\n g<\/jats:italic>\n -rate and OS was observed.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n \n This cohort study found that abiraterone and enzalutamide had comparable outcomes in a first-line mHSPC setting, with similar\n g<\/jats:italic>\n -rates and OS in both White and African American patients. There were no differences in survival or\n g<\/jats:italic>\n -rate between treatment based on race, comorbidities, and prostate cancer features, including Gleason score, PSA, and volume of disease.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.40730","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:01:03Z","timestamp":1762272063000},"page":"e2540730","source":"Crossref","is-referenced-by-count":5,"title":["Abiraterone vs Enzalutamide Among US Veterans With Metastatic Hormone-Sensitive Prostate Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Harshraj","family":"Leuva","sequence":"first","affiliation":[{"name":"University of Nebraska Medical Center, Omaha"},{"name":"James J. Peters Bronx Veterans Affairs Medical Center, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Teply","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeun-Hee Anna","family":"Park","sequence":"additional","affiliation":[{"name":"James J. Peters Bronx Veterans Affairs Medical Center, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Luhrs","sequence":"additional","affiliation":[{"name":"SUNY Downstate Health Sciences University, Brooklyn, New York"},{"name":"Veterans Affairs New York Harbor Healthcare System \u2013 Brooklyn Campus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhjot Singh","family":"Mundi","sequence":"additional","affiliation":[{"name":"Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York"},{"name":"James J. Peters Bronx Veterans Affairs Medical Center, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Bates","sequence":"additional","affiliation":[{"name":"Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York"},{"name":"James J. Peters Bronx Veterans Affairs Medical Center, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izak","family":"Faiena","sequence":"additional","affiliation":[{"name":"Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York"},{"name":"James J. Peters Bronx Veterans Affairs Medical Center, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tito","family":"Fojo","sequence":"additional","affiliation":[{"name":"Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York"},{"name":"James J. Peters Bronx Veterans Affairs Medical Center, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"Schoen","sequence":"additional","affiliation":[{"name":"Saint Louis Veterans Affairs Medical Center, St Louis, Missouri"},{"name":"Saint Louis University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"10","key":"zoi251115r1","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology.","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"zoi251115r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.19568","article-title":"Causes of death among patients with metastatic prostate cancer in the US From 2000 to 2016.","volume":"4","author":"Elmehrath","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi251115r4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"zoi251115r5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41391-022-00628-0","article-title":"Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database.","volume":"26","author":"Jani","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"zoi251115r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.1970","article-title":"Survival in patients with de novo metastatic prostate cancer.","volume":"7","author":"Schoen","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zoi251115r7","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial.","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi251115r8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi251115r9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"32","key":"zoi251115r10","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer.","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi251115r11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer.","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi251115r12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer.","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi251115r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.9433","article-title":"Treatment patterns and survival among veterans with de novo metastatic hormone-sensitive prostate cancer.","volume":"8","author":"Schoen","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi251115r14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(16)30633-7","article-title":"Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.","volume":"18","author":"Wilkerson","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4-5","key":"zoi251115r15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1053\/j.seminoncol.2019.11.004","article-title":"A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide.","volume":"46","author":"Leuva","year":"2019","journal-title":"Semin Oncol"},{"issue":"4","key":"zoi251115r16","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1158\/1078-0432.CCR-10-1762","article-title":"Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.","volume":"17","author":"Stein","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"10","key":"zoi251115r17","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1634\/theoncologist.2008-0075","article-title":"Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.","volume":"13","author":"Stein","year":"2008","journal-title":"Oncologist"},{"issue":"8","key":"zoi251115r18","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1158\/1078-0432.CCR-11-2275","article-title":"Analyzing the pivotal trial that compared sunitinib and IFN-a in renal cell carcinoma, using a method that assesses tumor regression and growth.","volume":"18","author":"Stein","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5","key":"zoi251115r19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/PPO.0b013e3181be1b90","article-title":"Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma.","volume":"15","author":"Stein","year":"2009","journal-title":"Cancer J"},{"issue":"2","key":"zoi251115r20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/oncolo\/oyac217","article-title":"Tumor growth rate informs treatment efficacy in metastatic pancreatic adenocarcinoma: application of a growth and regression model to pivotal trial and real-world data.","volume":"28","author":"Yeh","year":"2022","journal-title":"Oncologist"},{"issue":"15","key":"zoi251115r21","doi-asserted-by":"publisher","first-page":"9541","DOI":"10.1200\/JCO.2020.38.15_suppl.9541","article-title":"An FDA analysis of the association of tumor growth rate and overall and progression-free survival in metastatic non-small cell lung cancer (NSCLC) patients.","volume":"38","author":"Gong","year":"2020","journal-title":"J Clin Oncol"},{"key":"zoi251115r22","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1200\/CCI.21.00030","article-title":"Ascertainment of veterans with metastatic prostate cancer in electronic health records: demonstrating the case for natural language processing.","volume":"5","author":"Alba","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"issue":"24","key":"zoi251115r23","doi-asserted-by":"publisher","first-page":"6464","DOI":"10.1158\/1078-0432.CCR-20-1493","article-title":"Enhanced detection of treatment effects on metastatic colorectal cancer with volumetric CT measurements for tumor burden growth rate evaluation.","volume":"26","author":"Maitland","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"zoi251115r25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41391-022-00588-5","article-title":"Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases.","volume":"26","author":"Schoen","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3-4","key":"zoi251115r27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.seminoncol.2024.04.002","article-title":"Assessment of PSA responses and changes in the rate of tumor growth (g-rate) with immune checkpoint inhibitors in US Veterans with prostate cancer.","volume":"51","author":"Leuva","year":"2024","journal-title":"Semin Oncol"},{"key":"zoi251115r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105288","article-title":"Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent g-rate method ideal for real-world analyses.","volume":"107","author":"Leuva","year":"2024","journal-title":"EBioMedicine"},{"issue":"8","key":"zoi251115r29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.28444","article-title":"Abiraterone or enzalutamide for patients with metastatic castration-resistant prostate cancer.","volume":"7","author":"La","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi251115r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100261","article-title":"Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients.","volume":"6","author":"Kulkarni","year":"2021","journal-title":"ESMO Open"},{"issue":"4","key":"zoi251115r31","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0302-2838(23)01239-3","article-title":"Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study.","volume":"27","author":"Lee","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"zoi251115r32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41391-024-00792-5","article-title":"Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis.","volume":"27","author":"Ong","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"zoi251115r33","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"key":"zoi251115r2","unstructured":"Institute? NC. Cancer stat facts SEER. Prostate cancer. Accessed February 15, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html"},{"key":"zoi251115r24","unstructured":"Tumor growth rate analysis. 2016. Accessed February 4, 2016. http:\/\/CRAN.R-project.org\/package=tumgr"},{"key":"zoi251115r26","doi-asserted-by":"crossref","unstructured":"Zhou? M, Fojo? T, Schwartz? L, Bates? SE, Blagoev? KB. Cancer interception during treatment: using growth kinetics to create a continuous variable for assessing disease response.? bioRxiv. Preprint posted online September 11, 2024. doi:10.1101\/2024.09.10.612311","DOI":"10.1101\/2024.09.10.612311"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2840898\/leuva_2025_oi_251115_1761667444.18161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:01:06Z","timestamp":1762272066000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2840898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.40730","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]}}}